title: Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.
abstract: OBJECTIVE
  Pregabalin is effective in several neuropathic pain syndromes. This trial evaluated its efficacy, safety, and tolerability for treatment of painful HIV-associated neuropathy.
  
  
  METHODS
  This randomized, double-blind, placebo-controlled, parallel-group trial included a 2-week double-blind dose-adjustment (150-600 mg/day BID) phase, a 12-week double-blind maintenance phase, and an optional 3-month open label extension phase. The primary efficacy measure was the mean Numeric Pain Rating Scale (NPRS) score, an 11-point numeric rating scale. Secondary measures included Patient Global Impression of Change (PGIC) and sleep measurements.
  
  
  RESULTS
  Baseline mean NPRS score was 6.93 for patients randomized to pregabalin (n = 151) and 6.72 for those to placebo (n = 151). Pregabalin average daily dosage (SD) was 385.7 (160.3) mg/d. At endpoint, pregabalin and placebo showed substantial reductions in mean NPRS score from baseline: -2.88 vs -2.63, p = 0.3941. Pregabalin had greater improvements in NPRS score relative to placebo at weeks 1 (-1.14 vs -0.69, p = 0.0131) and 2 (-1.92 vs -1.43, p = 0.0393), and at weeks 7 (-3.22 vs -2.53 p = 0.0307) and 8 (-3.33 vs -2.53, p = 0.0156). At all other time points, differences between groups were not significant. Sleep measurements and 7-item PGIC did not differ among treatment groups; however, collapsed PGIC scores showed 82.8% of pregabalin and 66.7% of placebo patients rated themselves in 1 of the 3 "improved" categories (p = 0.0077). Somnolence and dizziness were the most common adverse events with pregabalin.
  
  
  CONCLUSIONS
  Pregabalin was well-tolerated, but not superior to placebo in the treatment of painful HIV neuropathy. Factors predicting analgesic response in HIV neuropathy warrant additional research.
  
  
  METHODS
  This Class II trial showed that pregabalin is not more effective than placebo in treatment of painful HIV neuropathy.
authors.affiliation: Mount Sinai School of Medicine, New York, NY, USA. david.simpson@mssm.edu
authors.forename: D M
authors.initials: DM
authors.lastname: Simpson
authors.forename: G
authors.initials: G
authors.lastname: Schifitto
authors.forename: D B
authors.initials: DB
authors.lastname: Clifford
authors.forename: T K
authors.initials: TK
authors.lastname: Murphy
authors.forename: E
authors.initials: E
authors.lastname: Durso-De Cruz
authors.forename: P
authors.initials: P
authors.lastname: Glue
authors.forename: E
authors.initials: E
authors.lastname: Whalen
authors.forename: B
authors.initials: B
authors.lastname: Emir
authors.forename: G N
authors.initials: GN
authors.lastname: Scott
authors.forename: R
authors.initials: R
authors.lastname: Freeman
mesh_terms: D000328:Adult; D000700:Analgesics / Q000627:therapeutic use*; D000704:Analysis of Variance; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology*; D010147:Pain Measurement; D000069583:Pregabalin; D012189:Retrospective Studies; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid